Screening för celiaki kan vara motiverad i högriskgrupper
(2004) In Läkartidningen 101(48). p.6-3918- Abstract
- Coeliac disease is widespread and occurs in 0.5-1 per cent of the population. Most sufferers show atypical symptoms and might well remain undiagnosed. Endomysial or human transglutaminase autoantibody levels of type IgA can be recommended as screening instruments combined with s-IgA for exclusion of such deficiency. In contrast, there is a high frequency of false-positive IgA gliadin antibody test results, especially where coeliac disease is common, as in chronic liver disease, diabetes, thyroid disease and conditions with chromosomal aberrations (Down syndrome and Turner syndrome). Despite this, gliadin antibodies of type IgA are still the best marker for coeliac disease in children under two years of age. While mass screening is not to... (More)
- Coeliac disease is widespread and occurs in 0.5-1 per cent of the population. Most sufferers show atypical symptoms and might well remain undiagnosed. Endomysial or human transglutaminase autoantibody levels of type IgA can be recommended as screening instruments combined with s-IgA for exclusion of such deficiency. In contrast, there is a high frequency of false-positive IgA gliadin antibody test results, especially where coeliac disease is common, as in chronic liver disease, diabetes, thyroid disease and conditions with chromosomal aberrations (Down syndrome and Turner syndrome). Despite this, gliadin antibodies of type IgA are still the best marker for coeliac disease in children under two years of age. While mass screening is not to be recommended, case finding is worthwhile in well defined risk groups, i.e. in cohorts with autoimmune disease or chromosomal aberrations or in relatives to anyone with coeliac disease. A positive biopsy is still the gold standard for diagnosis. (Less)
- Abstract (Swedish)
- Celiaki förekommer hos 0,5–1 procent av befolkningen.
Majoriteten av dem med celiaki har atypiska symtom
och är inte diagnostiserade.
Personer med vissa kromosomrubbningar eller annan
autoimmun sjukdom och nära släktingar till personer
med celiaki tillhör riskgrupper där screening
kan rekommenderas.
IgA-endomysie- eller IgA-transglutaminasantikroppar
har båda hög specificitet och hög sensitivitet för
celiaki och används idag för screening. Vid IgA-brist
kan IgG-antikroppar analyseras i stället.
IgA-gliadinantikroppar är ofta falskt positiva men är
trots detta den bästa markören hos barn under 2 år.
Celiaki är oftast... (More) - Celiaki förekommer hos 0,5–1 procent av befolkningen.
Majoriteten av dem med celiaki har atypiska symtom
och är inte diagnostiserade.
Personer med vissa kromosomrubbningar eller annan
autoimmun sjukdom och nära släktingar till personer
med celiaki tillhör riskgrupper där screening
kan rekommenderas.
IgA-endomysie- eller IgA-transglutaminasantikroppar
har båda hög specificitet och hög sensitivitet för
celiaki och används idag för screening. Vid IgA-brist
kan IgG-antikroppar analyseras i stället.
IgA-gliadinantikroppar är ofta falskt positiva men är
trots detta den bästa markören hos barn under 2 år.
Celiaki är oftast HLA-associerad, i de flesta fall till
DQ2 (80 procent) annars till DQ8 (20 procent). Ett alternativ
i framtiden kan vara att i vissa riskgrupper
först bestämma HLA-typ och därefter antikroppstiter.
Biopsi är fortfarande etablerad standardmetod för att
bekräfta diagnosen celiaki. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/133316
- author
- Sjöberg, Klas LU and Carlsson, Annelie LU
- organization
- alternative title
- Screening for celiac disease can be justified in high-risk groups
- publishing date
- 2004
- type
- Contribution to specialist publication or newspaper
- publication status
- published
- subject
- keywords
- Humans, Gliadin: immunology, English Abstract, Child, Celiac Disease: immunology, Celiac Disease: genetics, Celiac Disease: diagnosis, Celiac Disease: complications, Biological Markers: blood, Autoimmune Diseases: diagnosis, Adult, Autoimmune Diseases: complications, Transglutaminases: immunology, Risk Factors, Myosins: immunology, Immunoglobulin A: blood, Mass Screening
- in
- Läkartidningen
- volume
- 101
- issue
- 48
- pages
- 6 - 3918
- publisher
- Swedish Medical Association
- external identifiers
-
- scopus:10044254744
- pmid:15631226
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- yes
- id
- 4b062aaf-d3af-4e20-bbb4-fe355a75752e (old id 133316)
- alternative location
- http://ww2.lakartidningen.se/old/content_0448/pdf/3912_3919.pdf
- date added to LUP
- 2016-04-01 15:43:21
- date last changed
- 2023-04-18 17:41:42
@misc{4b062aaf-d3af-4e20-bbb4-fe355a75752e, abstract = {{Coeliac disease is widespread and occurs in 0.5-1 per cent of the population. Most sufferers show atypical symptoms and might well remain undiagnosed. Endomysial or human transglutaminase autoantibody levels of type IgA can be recommended as screening instruments combined with s-IgA for exclusion of such deficiency. In contrast, there is a high frequency of false-positive IgA gliadin antibody test results, especially where coeliac disease is common, as in chronic liver disease, diabetes, thyroid disease and conditions with chromosomal aberrations (Down syndrome and Turner syndrome). Despite this, gliadin antibodies of type IgA are still the best marker for coeliac disease in children under two years of age. While mass screening is not to be recommended, case finding is worthwhile in well defined risk groups, i.e. in cohorts with autoimmune disease or chromosomal aberrations or in relatives to anyone with coeliac disease. A positive biopsy is still the gold standard for diagnosis.}}, author = {{Sjöberg, Klas and Carlsson, Annelie}}, issn = {{0023-7205}}, keywords = {{Humans; Gliadin: immunology; English Abstract; Child; Celiac Disease: immunology; Celiac Disease: genetics; Celiac Disease: diagnosis; Celiac Disease: complications; Biological Markers: blood; Autoimmune Diseases: diagnosis; Adult; Autoimmune Diseases: complications; Transglutaminases: immunology; Risk Factors; Myosins: immunology; Immunoglobulin A: blood; Mass Screening}}, language = {{swe}}, number = {{48}}, pages = {{6--3918}}, publisher = {{Swedish Medical Association}}, series = {{Läkartidningen}}, title = {{Screening för celiaki kan vara motiverad i högriskgrupper}}, url = {{http://ww2.lakartidningen.se/old/content_0448/pdf/3912_3919.pdf}}, volume = {{101}}, year = {{2004}}, }